Novo Nordisk shares new clinical data for Wegovy in MASH treatment, utilizing the PLATINUM-Truveta analysis to benchmark performance against resmetirom and other investigational therapies.
Novo Nordisk is under scrutiny as new post hoc data from the ESSENCE trial and the PLATINUM-Truveta retrospective cohort analysis provide comparative insights into the efficacy of semaglutide 2.4 mg (Wegovy) for MASH patients. These findings are critical for investors as they establish the drug's performance profile against competitors like resmetirom regarding liver enzyme reduction and cardiometabolic improvements.
It compares the effectiveness of semaglutide 2.4 mg and resmetirom on liver enzymes and cardiometabolic markers in patients with MASH.
The new post hoc data focuses on changes in liver-related parameters for patients treated with semaglutide 2.4 mg.
Resmetirom is mentioned as a comparator in a retrospective cohort analysis, indicating competitive positioning in MASH.
Efruxifermin is mentioned in the title as an investigational asset being presented, though no results are disclosed.
Novo Nordisk is unveiling new post hoc data from the ESSENCE trial alongside a PLATINUM-Truveta retrospective analysis at the AASLD meeting. The findings evaluate the impact of semaglutide 2.4 mg on liver enzymes and cardiometabolic markers in patients with MASH, positioning the drug against competitors like Madrigal Pharmaceuticals' resmetirom.
It serves as a retrospective cohort study comparing the real-world effectiveness of semaglutide 2.4 mg against resmetirom in treating MASH patients.
The data highlights Novo Nordisk (Wegovy) and Madrigal Pharmaceuticals (resmetirom) as key players, with Akero Therapeutics also noted for its investigational asset efruxifermin.